"We will actively look at our business model to ensure we make a significant contribution to meeting the economic, healthcare, and environmental needs of China and its citizens," he said. "In addition, savings made as a result of proposed changes to our operational model will be passed on in the form of price reductions, ensuring our medicines are more affordable to Chinese patients."
His statement came just days before police in China widened their investigation into GSK operations in the country with a further 18 personnel arrested, according to state reports.
China's state news agency Xinhua reported that bribes to doctors and hospitals accounted for 30% of the current cost of GSK's drugs in the country. Xinhua also revealed details of the alleged corrupt practices by GSK employees.
"[Pharmaceutical representatives] invited doctors to join high-end academic conferences to help the practitioners increase influence in their fields," Xinhua reported. "They also established good personal relations with doctors by catering to their pleasures or offering them money, in order to make them prescribe more drugs."
The news agency quoted law enforcement officials as saying that between 7% and 10% of the sales price was funnelled to doctors' personal accounts. "Once a doctor agrees to cooperate with GSK China, the company will establish the doctor's file and pay a bonus to the doctor based on his or her prescriptions of the firm's drugs," it said.
"For those doctors who avoid receiving money, GSK China's salespeople would invite them to academic meetings or lectures and provide them with gifts, free travel after meetings, and lecture fees. In fact, many doctors received lecture fees even when the lectures did not exist." GSK responded to the Xinhua report with a written statement, saying, "This behaviour is a clear breach of GSK's systems, governance, values, and standards. We will continue to cooperate fully with the Chinese authorities in their investigation and take any and every action that is required."
Meanwhile, it has emerged that GSK was warned of potential corruption by an internal whistleblower at the beginning of the year. The Daily Telegraph has revealed that an email from an anonymous whistleblower sent on 16 January to the GSK board, its auditors, and several public relations staff, and copied to the Serious Fraud Office, describes many of the claims now being investigated by Chinese police.
1 A four month investigation by GSK "found no evidence of corruption or bribery." The company has previously said that it only became aware of the specific problems identified by police in July. 
